Clinical trials: Decitabine
Myelodysplastic Syndromes
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
The purpose of this study is to compare the response of patients with Intermediate or High Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.
- Trial name
- NCT01011283
- Testing
- decitabine, azacitidine
- Where
- 19 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects of genetically modified T cells and decitabine in treating patients with recurrent or refractory epithelial or non-epithelial ovarian, primary peritoneal, or fallopian tube cancer that…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03017131
- Testing
- Aldesleukin, Cyclophosphamide, Decitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Hypomethylating Agent, Venetoclax
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
The main objective of the study is to evaluate the efficacy and safety of maintenance therapy with hypomethylating agent and Venetoclax to improve leukemia free survival for high-risk myeloid malignancies after allogeneic…
- Conditions
- Hypomethylating Agent, Venetoclax, Myeloid Malignancy
- Trial name
- NCT05841771
- Testing
- Venetoclax, Azacitidine or decitabine
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non Small Cell Lung Cancer
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours.
- Trial name
- HyPeR (NCT02998567)
- Testing
- Guadecitabine, Pembrolizumab, ASTX727
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Colon Cancer
Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study
Background of the study: Colon cancer is the second leading cause of cancer-related death world wide. Although patients presenting with early disease (stage I-III) can be cured, prognosis varies from 90% in stage I to 50-80% in…
- Trial name
- DECO (NCT01882660)
- Testing
- Decitabine
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Acute Myeloid Leukemia
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute…
- Trial name
- NCT05360160
- Testing
- SNDX-5613, Venetoclax, ASTX727
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
This phase I trial is studying the side effects and best dose of decitabine in treating patients with myelodysplastic syndromes or acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00049582
- Testing
- decitabine, laboratory biomarker analysis, pharmacological study
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC.
- Trial name
- NCT02920008
- Testing
- guadecitabine, Treatment Choice (TC)
- Where
- 95 sites in United States, Belgium and 13 more
- Volunteers
- 302 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Engraft Failure, Relapse
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
The investigators will conduct this prospective and randomized clinical trial, to evaluate the hematopoietic reconstitution, GVHD and relapse rate of patients after allo-HSCT with decitabine containing conditional regimen and NAC…
- Conditions
- Engraft Failure, Relapse, GVHD
- Trial name
- NCT04945096
- Testing
- decitabine, Acetylcysteine, Semustine
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Myeloid, Acute
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
- Trial name
- NCT02348489
- Testing
- SGI-110 (guadecitabine), Treatment Choice
- Where
- 135 sites in United States, Australia and 22 more
- Volunteers
- 815 people
- Sponsor
- Astex Pharmaceuticals, Inc.